ID

31958

Descripción

Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01078155

Link

https://clinicaltrials.gov/show/NCT01078155

Palabras clave

Versiones (1)
  1. 9/10/18 9/10/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

9 de octubre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Rheumatoid Arthritis NCT01078155

Inglés

Eligibility Rheumatoid Arthritis NCT01078155

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with active early and long-standing ra according to american college of rheumatology (acr) 1987 revised criteria.
Descripción

Early Rheumatoid Arthritis Long-term

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3899278
UMLS CUI [1,2]
C0443252
patients with high disease activity das28 ≥ 5.1 according to the czech rheumatological society criteria.
Descripción

Rheumatoid arthritis disease activity high DAS28

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2368568
UMLS CUI [1,2]
C4481729
patients must fulfill national guidelines for use of anti-tnf: inadequate clinical response to at least one disease-modifying antirheumatic drug (dmard; methotrexate, sulphasalazine, leflunomide, hydroxychloroquine, or combinations) and oral glucocorticoids (equivalent to ≥ 5 mg prednisolone per day), (for romania except glucocorticoids); chest x-ray, purified protein derivative (ppd)-skin test, quantiferon/tuberculosis (tb) gold test (if available) negative for tb.
Descripción

Guidelines Fulfill Use of Anti-TNF drug | DMARDs Quantity Response Inadequate | DMARDs | Methotrexate | Sulfasalazine | leflunomide | Hydroxychloroquine | Combined Modality Therapy | Glucocorticoids Oral | Equivalent Prednisolone U/day | Tuberculosis test negative Chest X-ray | PPD skin test negative | QuantiFERON-TB test without active tuberculosis

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0162791
UMLS CUI [1,2]
C1550543
UMLS CUI [1,3]
C1524063
UMLS CUI [1,4]
C1562242
UMLS CUI [2,1]
C0242708
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C1704632
UMLS CUI [2,4]
C0205412
UMLS CUI [3]
C0242708
UMLS CUI [4]
C0025677
UMLS CUI [5]
C0036078
UMLS CUI [6]
C0063041
UMLS CUI [7]
C0020336
UMLS CUI [8]
C0009429
UMLS CUI [9,1]
C0017710
UMLS CUI [9,2]
C1527415
UMLS CUI [10,1]
C0205163
UMLS CUI [10,2]
C0032950
UMLS CUI [10,3]
C0456683
UMLS CUI [11,1]
C2242735
UMLS CUI [11,2]
C0039985
UMLS CUI [12]
C1328483
UMLS CUI [13]
C3161222
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have had a history of tnf blocking or rituximab therapy.
Descripción

Tumor necrosis factor alpha inhibitor | rituximab

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4521709
UMLS CUI [2]
C0393022
patients who are being treated or will be treated with drug at risk of interaction with adalimumab (humira).
Descripción

Pharmaceutical Preparations At risk Interaction Adalimumab | Pharmaceutical Preparations At risk Interaction Humira

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0687133
UMLS CUI [1,4]
C1122087
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1444641
UMLS CUI [2,3]
C0687133
UMLS CUI [2,4]
C1171255
pregnant females and/or females without adequate method of contraception.
Descripción

Pregnancy | Gender Contraceptive methods Absent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0700589
UMLS CUI [2,3]
C0332197
patients who didn't receive prior dmard therapy.
Descripción

DMARD Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0242708
UMLS CUI [1,2]
C0332197
patients participating in another study or clinical trial.
Descripción

Study Subject Participation Status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
patients with severe osteoporosis (t-score [number that indicates whether or not bone loss has occurred] of ≤ -2.5 and/or prior vertebral fracture/s).
Descripción

Severe osteoporosis | T score Bone Density | Vertebral Fractures

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1859443
UMLS CUI [2,1]
C3854607
UMLS CUI [2,2]
C0005938
UMLS CUI [3]
C0080179
patients with a history of total hip replacement of both extremities.
Descripción

Total Hip Replacement Extremities Both

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0040508
UMLS CUI [1,2]
C0015385
UMLS CUI [1,3]
C1706086
patients who currently receive and/or received bone metabolism modulating agents including selective estrogen receptor modulators (serms), bisphosphonates, parathyroid hormone or anti-receptor activator of nuclear factor-kappab ligand (rankl) therapy.
Descripción

Pharmaceutical Preparations Modulating Bone metabolism | Selective Estrogen Receptor Modulators | Diphosphonates | Parathyroid Hormone | RANK Ligand Inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0443264
UMLS CUI [1,3]
C0596204
UMLS CUI [2]
C0732611
UMLS CUI [3]
C0012544
UMLS CUI [4]
C0030520
UMLS CUI [5]
C3665044
subjects who are not eligible for tnf-blocking therapy according to the czech national registry (attra).
Descripción

Patients Ineligible TNF alpha inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1512714
UMLS CUI [1,3]
C4521709
Volver a la parte superior de la página

Similar models

Eligibility Rheumatoid Arthritis NCT01078155

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Early Rheumatoid Arthritis Long-term
Item
patients with active early and long-standing ra according to american college of rheumatology (acr) 1987 revised criteria.
boolean
C3899278 (UMLS CUI [1,1])
C0443252 (UMLS CUI [1,2])
Rheumatoid arthritis disease activity high DAS28
Item
patients with high disease activity das28 ≥ 5.1 according to the czech rheumatological society criteria.
boolean
C2368568 (UMLS CUI [1,1])
C4481729 (UMLS CUI [1,2])
Guidelines Fulfill Use of Anti-TNF drug | DMARDs Quantity Response Inadequate | DMARDs | Methotrexate | Sulfasalazine | leflunomide | Hydroxychloroquine | Combined Modality Therapy | Glucocorticoids Oral | Equivalent Prednisolone U/day | Tuberculosis test negative Chest X-ray | PPD skin test negative | QuantiFERON-TB test without active tuberculosis
Item
patients must fulfill national guidelines for use of anti-tnf: inadequate clinical response to at least one disease-modifying antirheumatic drug (dmard; methotrexate, sulphasalazine, leflunomide, hydroxychloroquine, or combinations) and oral glucocorticoids (equivalent to ≥ 5 mg prednisolone per day), (for romania except glucocorticoids); chest x-ray, purified protein derivative (ppd)-skin test, quantiferon/tuberculosis (tb) gold test (if available) negative for tb.
boolean
C0162791 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C1524063 (UMLS CUI [1,3])
C1562242 (UMLS CUI [1,4])
C0242708 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1704632 (UMLS CUI [2,3])
C0205412 (UMLS CUI [2,4])
C0242708 (UMLS CUI [3])
C0025677 (UMLS CUI [4])
C0036078 (UMLS CUI [5])
C0063041 (UMLS CUI [6])
C0020336 (UMLS CUI [7])
C0009429 (UMLS CUI [8])
C0017710 (UMLS CUI [9,1])
C1527415 (UMLS CUI [9,2])
C0205163 (UMLS CUI [10,1])
C0032950 (UMLS CUI [10,2])
C0456683 (UMLS CUI [10,3])
C2242735 (UMLS CUI [11,1])
C0039985 (UMLS CUI [11,2])
C1328483 (UMLS CUI [12])
C3161222 (UMLS CUI [13])
Item Group
C0680251 (UMLS CUI)
Tumor necrosis factor alpha inhibitor | rituximab
Item
patients who have had a history of tnf blocking or rituximab therapy.
boolean
C4521709 (UMLS CUI [1])
C0393022 (UMLS CUI [2])
Pharmaceutical Preparations At risk Interaction Adalimumab | Pharmaceutical Preparations At risk Interaction Humira
Item
patients who are being treated or will be treated with drug at risk of interaction with adalimumab (humira).
boolean
C0013227 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0687133 (UMLS CUI [1,3])
C1122087 (UMLS CUI [1,4])
C0013227 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0687133 (UMLS CUI [2,3])
C1171255 (UMLS CUI [2,4])
Pregnancy | Gender Contraceptive methods Absent
Item
pregnant females and/or females without adequate method of contraception.
boolean
C0032961 (UMLS CUI [1])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
DMARD Absent
Item
patients who didn't receive prior dmard therapy.
boolean
C0242708 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Study Subject Participation Status
Item
patients participating in another study or clinical trial.
boolean
C2348568 (UMLS CUI [1])
Severe osteoporosis | T score Bone Density | Vertebral Fractures
Item
patients with severe osteoporosis (t-score [number that indicates whether or not bone loss has occurred] of ≤ -2.5 and/or prior vertebral fracture/s).
boolean
C1859443 (UMLS CUI [1])
C3854607 (UMLS CUI [2,1])
C0005938 (UMLS CUI [2,2])
C0080179 (UMLS CUI [3])
Total Hip Replacement Extremities Both
Item
patients with a history of total hip replacement of both extremities.
boolean
C0040508 (UMLS CUI [1,1])
C0015385 (UMLS CUI [1,2])
C1706086 (UMLS CUI [1,3])
Pharmaceutical Preparations Modulating Bone metabolism | Selective Estrogen Receptor Modulators | Diphosphonates | Parathyroid Hormone | RANK Ligand Inhibitor
Item
patients who currently receive and/or received bone metabolism modulating agents including selective estrogen receptor modulators (serms), bisphosphonates, parathyroid hormone or anti-receptor activator of nuclear factor-kappab ligand (rankl) therapy.
boolean
C0013227 (UMLS CUI [1,1])
C0443264 (UMLS CUI [1,2])
C0596204 (UMLS CUI [1,3])
C0732611 (UMLS CUI [2])
C0012544 (UMLS CUI [3])
C0030520 (UMLS CUI [4])
C3665044 (UMLS CUI [5])
Patients Ineligible TNF alpha inhibitor
Item
subjects who are not eligible for tnf-blocking therapy according to the czech national registry (attra).
boolean
C0030705 (UMLS CUI [1,1])
C1512714 (UMLS CUI [1,2])
C4521709 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial